drugset / Trial / NCT02007720

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

NCT02007720 ↗

Phase 3 Terminated 876 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Timeline

Start
2014-03-12
Primary completion
2017-03-27
Completion
2017-06-16

Outcome

Outcome not reported

Stopped: “Study was terminated based on results from pivotal adult AHF study CRLX030A2301”

Drugs

EvaluationDrugModalityDoseRoute
Subject Serelaxin Protein / enzyme biologic 30 ug/kg Intravenous

Indications